 Business Wire India EXKIVITY is the First Category-1 Innovative Drug Approved for Takeda China Following a Phase 2 Global Pivotal Study Approval Based on Data from the Phase 12 Clinical Trial Demonstrating EXKIVITYs Clinical Benefit and Durable Responses in EGFR Exon20 Insertion NSCLC Results Demonstrated a Confirmed Overall Response Rate ORR of 28... The post Takedas EXKIVITY mobocertinib Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Pa... 